Pathogenesis of osteopenia/osteoporosis induced by highly active anti-retroviral therapy for AIDS.
Ann N Y Acad Sci
; 1068: 297-308, 2006 Apr.
Article
en En
| MEDLINE
| ID: mdl-16831930
The advent of highly active anti-retroviral therapy (HAART) has dramatically decreased the rate of AIDS-related mortality and significantly extended the life span of patients with AIDS. A variety of metabolic side effects are associated with these therapies, one of which is metabolic bone disease. A higher prevalence of osteopenia and osteoporosis in HIV-infected patients receiving anti-retroviral therapy than in patients not on therapy has now been reported in several studies. Several factors have been demonstrated to influence HIV-associated decreases in bone mineral density (BMD), including administration of nucleoside reverse transcriptase inhibitors (NRTIs). In this article, discussion will focus on the molecular pathogenesis and treatment of HAART-associated osteopenia and osteoporosis.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Osteoporosis
/
Enfermedades Óseas Metabólicas
/
Resorción Ósea
/
Síndrome de Inmunodeficiencia Adquirida
/
Terapia Antirretroviral Altamente Activa
Tipo de estudio:
Etiology_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Ann N Y Acad Sci
Año:
2006
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Estados Unidos